-
Product Insights
NewNet Present Value Model: NRX Pharmaceuticals Inc’s Cycloserine + Lurasidone Hydrochloride
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ketamine in Bipolar Disorder (Manic Depression)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ketamine in Bipolar Disorder (Manic Depression) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ketamine in Bipolar Disorder (Manic Depression) Drug Details: Ketamine (NRX-100)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Cycloserine + Lurasidone Hydrochloride) in Bipolar Disorder (Manic Depression)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cycloserine + Lurasidone Hydrochloride) in Bipolar Disorder (Manic Depression) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cycloserine + Lurasidone Hydrochloride) in Bipolar Disorder...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IRX-4204 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IRX-4204 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IRX-4204 in Parkinson's Disease Drug Details: IRX-4204 (NRX-4204) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IRX-4204 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IRX-4204 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IRX-4204 in Non-Small Cell Lung Cancer Drug Details: IRX-4204 (NRX-4204)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IRX-4204 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IRX-4204 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IRX-4204 in...
-
Product Insights
Pyelonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Pyelonephritis - Drugs In Development, 2023’, provides an overview of the Pyelonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pyelonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Bipolar Disorder (Manic Depression) – Drugs In Development, 2023
Global Markets Direct’s, ‘Bipolar Disorder (Manic Depression) - Drugs In Development, 2023’, provides an overview of the Bipolar Disorder (Manic Depression) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Urinary Tract Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Urinary Tract Infections - Drugs In Development, 2023’, provides an overview of the Urinary Tract Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urinary Tract Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Post-Traumatic Stress Disorder (PTSD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Post-Traumatic Stress Disorder (PTSD) - Drugs In Development, 2023’, provides an overview of the Post-Traumatic Stress Disorder (PTSD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...